Paradoxical Reduction in HDL-C With Fenofibrate and Thiazolidinedione Therapy in Type 2 Diabetes: The ACCORD Lipid Trial

OBJECTIVE: To determine the occurrence of extremely low HDL cholesterol (HDL-C) among participants in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid Trial and to examine the relationship of this finding with treatment with fenofibrate and thiazolidinedione (TZD). RESEARCH DESIG...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Linz, Peter E., Lovato, Laura C., Byington, Robert P., O’Connor, Patrick J., Leiter, Lawrence A., Weiss, Daniel, Force, Rex W., Crouse, John R., Ismail-Beigi, Faramarz, Simmons, Debra L., Papademetriou, Vasilios, Ginsberg, Henry N., Elam, Marshall B.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Diabetes Association 2014
Konular:
Clinical Care/Education/Nutrition/Psychosocial Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3931389/
https://ncbi.nlm.nih.gov/pubmed/24296848
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc13-0790
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller